Ropes Wealth Advisors LLC trimmed its position in Celgene Co. (NASDAQ:CELG) by 52.1% in the 1st quarter, HoldingsChannel reports. The fund owned 4,001 shares of the biopharmaceutical company’s stock after selling 4,354 shares during the quarter. Ropes Wealth Advisors LLC’s holdings in Celgene were worth $377,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in CELG. Oregon Public Employees Retirement Fund boosted its stake in Celgene by 9,691.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 16,495,997 shares of the biopharmaceutical company’s stock valued at $257,000 after acquiring an additional 16,327,522 shares in the last quarter. Norges Bank acquired a new stake in Celgene in the fourth quarter valued at approximately $484,390,000. Parnassus Investments CA boosted its stake in Celgene by 1,766.7% in the fourth quarter. Parnassus Investments CA now owns 2,800,000 shares of the biopharmaceutical company’s stock valued at $179,452,000 after acquiring an additional 2,650,000 shares in the last quarter. BlackRock Inc. boosted its stake in Celgene by 2.8% in the fourth quarter. BlackRock Inc. now owns 53,650,909 shares of the biopharmaceutical company’s stock valued at $3,438,486,000 after acquiring an additional 1,459,100 shares in the last quarter. Finally, AQR Capital Management LLC boosted its stake in Celgene by 38.8% in the third quarter. AQR Capital Management LLC now owns 4,090,345 shares of the biopharmaceutical company’s stock valued at $366,044,000 after acquiring an additional 1,143,027 shares in the last quarter. Institutional investors own 74.92% of the company’s stock.

Shares of NASDAQ:CELG traded up $0.85 on Monday, hitting $94.99. 399,473 shares of the company were exchanged, compared to its average volume of 10,548,589. Celgene Co. has a 1-year low of $58.59 and a 1-year high of $95.30. The company has a current ratio of 2.23, a quick ratio of 2.12 and a debt-to-equity ratio of 3.21. The company has a market capitalization of $66.18 billion, a P/E ratio of 12.48, a PEG ratio of 0.43 and a beta of 1.71.

Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, January 31st. The biopharmaceutical company reported $2.39 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.32 by $0.07. Celgene had a net margin of 26.48% and a return on equity of 114.66%. The business had revenue of $4.04 billion during the quarter, compared to the consensus estimate of $3.98 billion. During the same period in the previous year, the firm posted $2.00 earnings per share. Equities analysts forecast that Celgene Co. will post 10.01 EPS for the current year.

In related news, Director James J. Loughlin sold 23,466 shares of the firm’s stock in a transaction on Thursday, February 7th. The shares were sold at an average price of $87.29, for a total transaction of $2,048,347.14. Following the completion of the transaction, the director now owns 62,102 shares of the company’s stock, valued at $5,420,883.58. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Ernest Mario bought 2,000 shares of Celgene stock in a transaction that occurred on Tuesday, February 12th. The shares were acquired at an average cost of $89.99 per share, with a total value of $179,980.00. The disclosure for this purchase can be found here. Insiders own 0.39% of the company’s stock.

Several equities research analysts have weighed in on CELG shares. Leerink Swann downgraded shares of Celgene from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 3rd. BidaskClub upgraded shares of Celgene from a “strong sell” rating to a “sell” rating in a research note on Friday, January 4th. Robert W. Baird upgraded shares of Celgene from a “neutral” rating to an “outperform” rating and set a $92.00 target price for the company in a research note on Friday, January 4th. Zacks Investment Research upgraded shares of Celgene from a “hold” rating to a “strong-buy” rating and set a $99.00 target price for the company in a research note on Wednesday, January 23rd. Finally, Canaccord Genuity downgraded shares of Celgene from a “buy” rating to a “hold” rating in a research note on Thursday, January 3rd. One investment analyst has rated the stock with a sell rating, eighteen have issued a hold rating and nine have given a buy rating to the stock. Celgene has an average rating of “Hold” and an average target price of $99.41.

COPYRIGHT VIOLATION WARNING: This story was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://theolympiareport.com/2019/04/15/celgene-co-celg-holdings-trimmed-by-ropes-wealth-advisors-llc.html.

About Celgene

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Further Reading: Why are percentage decliners important?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.